| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Alnylam Pharmaceuticals, Inc. (ALNY) has 11 insiders with recent SEC Form 4 filings, including 4 buys and 35 sells. ALNY is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 79.1K | $22.66M | - | |
| CFO | 58.4K | $16.73M | - | |
| VP | 29.8K | $8.52M | - | |
| VP | 23.7K | $6.78M | - | |
| Dir | 23.2K | $6.65M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2016 | Greene Barry E | President | Sale+OE | 31,825 | $42.99 | $1,368,127.63 | -10.1% | |
| Nov 30, 2016 | Vaishnaw Akshay56 | EVP, R&D, CMO | Sale+OE | 29,165 | $44.99 | $1,311,997.85 | -46.5% | |
| Oct 13, 2016 | Pyott David E I | Director | Buy | 27,900 | $37.00 | $1,032,327.90 | New | |
| Jul 20, 2016 | Maraganore John | CEO | Sale+OE | 30,151 | $64.69 | $1,950,590.03 | -4.2% | |
| Apr 20, 2016 | Maraganore John | Chief Executive Officer | Sale+OE | 30,151 | $67.46 | $2,033,972.21 | -4.3% | |
| Mar 9, 2016 | Bonney Michael W | Director | Buy | 2,000 | $58.36 | $116,720.00 | +100.0% | |
| Feb 23, 2016 | Alnylam Pharmaceuticals, Inc. | 10% Owner | Sell | 1,000,000 | $7.18 | $7,180,000.00 | -17.0% | |
| Feb 22, 2016 | Gros David-Alexandre C | SVP, Chief Business Officer | Buy | 1,000 | $62.75 | $62,749.00 | +1,000% | |
| Jan 20, 2016 | Maraganore John | Chief Executive Officer | Sale+OE | 30,152 | $71.78 | $2,164,218.65 | -1.3% | |
| Dec 4, 2015 | Sharp Philip A45 | Director | Sale+OE | 30,000 | $109.00 | $3,270,000.00 | -17.6% |